Soltero Cardiovascular Research Center

Patient-centered model aimed to improve healthcare through innovative medicines and therapies

The Soltero Cardiovascular Research Center began at Baylor Dallas in 1987 to bring clinically relevant cardiology research studies to Baylor Scott & White Health. The Center is improving patients' lives through innovative research to understand, prevent, and even reverse heart disease.

The Center is nationally recognized for conducting high-quality studies on cardiovascular problems, medications, and surgical procedures. Its studies have focused on cardiovascular problems caused by:

  • Diabetes
  • Hardening of arteries
  • High blood pressure
  • Increased levels of lipoprotein molecules in the blood

Soltero Cardiovascular Research Center is proud to be a MAGI Blue Ribbon Site


Our mission

  • Perform the highest quality clinical research
  • Involve the Center in important practice-altering studies
  • Facilitate high-quality care for our patients
  • Promote innovative, creative, and original research
  • Wisely use funds generated or generously donated
  • Educate patients, Baylor Scott & White personnel, and our community on research concepts and results

Current Research

AAA - Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the treatment of abdominal aortic aneurysms. 

Learn more

ALIDIAL - A phase III trial to evaluate the efficacy and safety of biweekly alirocumab in patients on a stable dialysis regimen.

Learn more

CLEAR - A randomized, double-blind, placebo-controlled study to assess the effects of bempedoic acid (ETC-1002) on the occurrence of major cardiovascular events in patients with or at high risk for cardiovascular disease who are statin intolerant.

Learn more

DREAM - A double-blind, randomized, sham-procedure-controlled, parallel-group efficacy and safety study of Allogeneic Mesenchymal Precursor Cells (rexlemesrocel-L) in patients with chronic heart failure due to left ventricular systolic dysfunction of either ischemic or nonischemic etiology.

Learn more

Emperor Preserved - A phase III randomized, double-blind trial to evaluate the efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic heart failure with preserved ejection fraction (HFpEF).

Learn more

GREAT – A global registry for endovascular aortic treatment outcomes evaluation.

Learn more

GUARD –A multicenter, prospective, parallel-group, double-blind, randomized, placebo-controlled, phase II study of BB3 to assess the safety and efficacy of BB3 in patients developing acute kidney injury after cardiac surgery.

Learn more

HUMANITY – An assessment of humacyte’s human acellular vessel in patients needing renal replacement therapy: A comparison with ePTFE grafts as conduits for hemodialysis.

Learn more

On-X – A longitudinal, randomized study comparing the On-X valve on low dose anticoagulation to concomitant control groups of On-X valves receiving standard Coumadin/aspirin therapy.

Learn more

PARADISE – A multi-center, randomized, double-blind, active-controlled, parallel-group Phase III study to evaluate the efficacy and safety of LCZ696 (Entresto) compared to Ramipril on morbidity and mortality in high risk patients following an acute myocardial infection.

Learn more

Perspective - A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 (Entresto™) compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction.

Learn more

QUARK 309 – A randomized, double-blind, placebo controlled, Phase III study to evaluate the efficacy and safety of QPI-1002 for the prevention of major adverse kidney events in subjects at high risk for acute kidney injury (AKI) following cardiac surgery. 

Learn more

SPYRAL PIVOTAL – SPYRAL HTN-OFF MED - A multi-center, prospective, single blinded, 1:1 randomized, sham-procedure controlled global clinical study of renal denervation with the Symplicity Spyral™ multi-electrode renal denervation system in patients with uncontrolled hypertension in the absence of antihypertensive medication.

Learn more

SPYRAL HTN-ON MED - A multi-center, prospective, single blinded, 2:1 (treatment to control) randomized, sham-procedure controlled global clinical study of renal denervation with the Symplicity Spyral™ multi-electrode renal denervation system in patients with uncontrolled hypertension on standard medical therapy.

Learn more

Physician Leadership

Cara Anne East, MD

Medical Director, Soltero Cardiovascular Research Center
Clinical Professor, Texas A&M College of Medicine

Research Team

Merielle Boatman, MBA, BAAS

Kyle Bass, MD

Clinical Research Coordinator II

Pamela Coker, RN, CCRC

Poupak Moshayedi, RN, CCRC

JaKarsha Culton, RN, CCRC

Aaron Mercado-Reza, MS, BA

Clinical Research Coordinator I

Janet Jackson, BS HIM

Data Enrollment Analyst

Elizabeth Beene

Research Enrollment Analyst

LaTosha Williams

Regulatory Specialist

Shanet Stefanos, BA

Research Enrollment Analyst
Recruitment and Marketing Specialist

Jackie Clark

Administrative Assistant I

Mary Jessie Guerra

Natalia Feliz

Clinical Research Coordinator

What it means to be a Blue Ribbon Site

A commitment to excellence is a unifying principle that can inspire a team to go beyond just doing their jobs. While a culture of excellence includes ingredients like a shared vision, mastery of roles, accountability and collaboration, the key ingredients are pride and inspiration. Clinical research is a tough, often frustrating business that needs the inspiration to rise above mediocrity and deserves pride when excellence is achieved. Excellent sites exhibit the following characteristics:

  • Experience
  • Stability
  • Quick study start-up
  • Access to a large patient database
  • Consistently meet or exceed enrollment commitments
  • Generate high-quality data in a timely manner

About Magi Blue Ribbon Site

MAGI is an organization that assists in streamlining clinical research by standardizing best practices for clinical research operations, business, and regulatory compliance. There are 10,000+ members represent clinical research sponsors, sites and CROs. MAGI is operated by First Clinical Research LLC, a company dedicated to advancing the practice of clinical research.

Contact Us

Merielle Boatman
Fax: 214.820.6236

Soltero Cardiovascular Research Center
621 N Hall St., Suite 530
Dallas, TX 75226